Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known? - Suppr | 超能文献

Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?

作者信息

van Maarseveen E, van Zuilen A D

出版信息

Clin Pharmacol Ther. 2013 Apr;93(4):306-7. doi: 10.1038/clpt.2012.214. Epub 2012 Oct 24.

DOI:10.1038/clpt.2012.214

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?

Clin Pharmacol Ther. 2013 Apr;93(4):306-7. doi: 10.1038/clpt.2012.214. Epub 2012 Oct 24.

2

Response to "pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?".

Clin Pharmacol Ther. 2013 Apr;93(4):307-8. doi: 10.1038/clpt.2012.234. Epub 2012 Dec 6.

3

CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.细胞色素P450 3A5（CYP3A5）基因分型而非细胞色素P450 3A4（CYP3A4）*1b、CYP3A4*22或血细胞比容可预测巴西肾移植患者的他克莫司剂量需求。

Clin Pharmacol Ther. 2013 Aug;94(2):201-2. doi: 10.1038/clpt.2013.68. Epub 2013 Apr 2.

4

Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".

Clin Pharmacol Ther. 2013 Aug;94(2):202-3. doi: 10.1038/clpt.2013.94. Epub 2013 May 9.

5

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.在体内 CYP3A4 活性、CYP3A5 基因型和红细胞压积可预测肾移植患者他克莫司的剂量需求和清除率。

Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8.

6

Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.接受含利托那韦的 cART 的 HIV 感染患者移植前他克莫司药代动力学曲线：一项初步研究。

Transplantation. 2013 Jan 27;95(2):397-402. doi: 10.1097/TP.0b013e3182734651.

7

Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.一名肾移植儿童中环孢素与氨氯地平之间的药代动力学相互作用

Transplantation. 2012 Apr 15;93(7):e29-30. doi: 10.1097/TP.0b013e318249b180.

8

Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.成人肾移植患者他克莫司的群体药代动力学：CYP3A5 基因型对起始剂量的影响。

Ther Drug Monit. 2014 Feb;36(1):62-70. doi: 10.1097/FTD.0b013e31829f1ab8.

9

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.肾移植术后早期单、双剂量他克莫司的药代动力学和药物基因组学比较。

Transplantation. 2012 Nov 27;94(10):1013-9. doi: 10.1097/TP.0b013e31826bc400.

10

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.CYP3A5基因多态性对肾移植受者他克莫司药代动力学及急性排斥反应的影响：单中心经验

Int J Clin Pract Suppl. 2015 May(183):16-22. doi: 10.1111/ijcp.12662.

引用本文的文献

1

Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.凯珀斯和范霍夫对诺伊霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文作出回应。

Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24.

2

Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.异基因造血细胞移植中免疫抑制剂的药代动力学、药效学和药物基因组学：第二部分。

Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9.